Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer

Median OS Not Yet Reached In PD-L1-Positive Patients

Waterfalls
• Source: Shutterstock

More from Clinical Trials

More from R&D